Osteoporosis with Pathological Fracture When First-Line Bisphosphonates or Anti-Resorptive Therapy Have Not Met Treatment Targets
This protocol addresses osteoporosis with pathological fracture in patients who have completed a course of first-line anti-resorptive therapy but whose bone density and turnover marker targets remain unmet — warranting escalation to a more intensive treatment approach.
Previous Treatment & Failure Condition
The prior regimen included agents such as alendronate, risedronate, zoledronate, or denosumab, potentially combined with calcium, vitamin D, and exercise. Escalation is indicated when those therapies failed to achieve:
- Total hip T-score ≥ −2.5 or an improvement of at least 0.2 units (3%) over 3 years
- Lumbar spine T-score improvement of at least 0.5 units (6%) over 3 years
- Adequate suppression of serum P1NP and CTX at 3–6 months
- Serum 25-hydroxyvitamin D above 20 ng/mL
Current Protocol — Treatment Approach
This protocol centres on a time-limited course of osteoanabolic therapy, followed by a planned transition to anti-resorptive treatment to consolidate bone mineral density gains. The specific sequence, agent selection, and consolidation strategy are detailed in the full protocol.
Full regimen, agent details, and algorithm available via the link below.
Treatment Targets
- P1NP above reference range, or an increase greater than the least significant change, during the osteoanabolic phase
- Total hip T-score ≥ −2.5 or improvement of at least 0.2 units (3%)
- Lumbar spine T-score improvement of at least 0.5 units (6%)
References
DOI: 10.1136/bmj‑2024-081250
- Use of teriparatide and abaloparatide is still recommended for 18–24 months owing to limited evidence for safety and efficacy beyond this period.
- Although residual effects on fracture risk reduction exist for up to 18 months after cessation of therapy, teriparatide or abaloparatide should be followed by anti-resorptives (raloxifene, bisphosphonates, or denosumab) after discontinuation to consolidate or further extend BMD gains.
- BMD gains are reversed nearly to baseline over one year following discontinuation of romosozumab and should be prevented by transition to anti-resorptive therapy.
- Studies show that transitioning from teriparatide or romosozumab to denosumab leads to continued BMD increases, with the romosozumab-to-denosumab sequence yielding gains equivalent to seven years of denosumab alone, as seen in the FRAME and FREEDOM studies.
- Bisphosphonates also help to maintain or increase BMD after osteoanabolic therapy, as observed in the ACTIVExtend and ARCH trials.
- On teriparatide or abaloparatide, aim for P1NP above reference range or change greater than LSC.
- In patients with low T-scores, a target of T ≥ −2.5 is generally adopted as an appropriate threshold for discontinuation of therapy, on the basis of the FLEX and HORIZON-PFT trials, and endorsed by the latest American Society of Bone and Mineral Research guidance on goal directed osteoporosis treatment.
- Experts recommend an improvement in total hip T-score of at least 0.2 units (3%) and in lumbar spine T-score of at least 0.5 units (6%), on the basis of reasonable chances of attaining such increments over three years by most therapies, including anti-resorptives.
View source ↗